In AD, reduced levels of anti-inflammatory SCFAs such as acetate, butyrate, and propionate impair T-reg cell activation and allow Th2-driven inflammation through cytokines like IL-4, IL-5, and IL-13 [17,18]. The gene discussed is IL4; the disease is Alzheimer disease.